anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed is polyoxypropylenepolyoxyethylene vitamin E, represented by formula (I). It is prepared by subjecting vitamin E to polyethoxylation and then, to polypropoxylation to a proper extent. The vitamin E is of superior anti-oxidation activity with water solubility. The bent chain of the polyoxypropylenepolyoxyethylene vitamin E increases the cross-sectional area of the whole molecule, making it difficult for the molecule to penetrate into the skin. It is very safe to apply to the skin. The polyoxypropylenepolyoxyethylene vitamin E has superb surface activity by forming close bilayer vesicle structures, like phospholipids or dialkyl surfactants, so it can be advantageously used in the cosmetic industry, the food industry and the medical industry. In said formula, R1 is -(OCH2CH2)m- wherein m is an integer of 0 to 150; R2 is (a) wherein n is an integer of 1 to 200; A is (b) or (c); B is -CH3 at the 5-, 7- or 8-position of vitamin E; and p is an integer of 1 or 3.
Specific binding members, particularly human antibodies, particularly recombinant antibodies, and fragments thereof, which are capable of binding to and recognizing neurons in the CNS and eliciting responses in CNS neurons are provided. The antibodies are useful in the diagnosis and treatment of conditions associated with nerve damage, injury or degeneration and neurodegenerative disease, and in particular in the treatment or alleviation of stroke or cerebral ischemia. The antibodies, variable regions or CDR domain sequences. thereof, and fragments thereof of the invention may also be used in therapy in combination with chemotherapeutics, immune modulators, or neuroactive agents and/or with other antibodies or fragments thereof. The antibodies or active fragments thereof may be used in therapy for stroke or cerebral ischemia alone or in combination with thrombolytics such as TPA. Antibodies are exemplified by the antibodies lgM12 and lgM42 whose sequences are provided herein.
The invention provides a drug for treating tinea of feet and hands and a preparation method thereof. The drug is prepared from 5-7 parts by weight of radix sophorae flavescentis, 5-7 parts by weight of rhizoma polygonati, 3-5 parts by weight of paniculate swallowwort root, 2-3 parts by weight of honeysuckle flower, 2-3 parts by weight of cortex dictamni and 1-2 parts by weight of fruits of Azadirachta Indica. The drug is prepared through an immersion method. The above traditional Chinese medicine components are combined reasonably and produce synergism. Repeated tests prove that the drug has effects of clearing heat and promoting dieresis, removing toxins and killing insects, dispelling wind and arresting itching, and nourishing blood and treating tinea. In preparation, an alcoholic solution is used in twice so that drug waste is avoided.
Approval from Ethical Committee of Faculty of Medicine University of Indonesia was acquired prior conducting the study. Subjects were given informed consent before enrolling the study.Subjects sat in cross leg sitting position: patients sit with both thighs abducted, knees flexed medially, each feet soles were under their contralateral thighs. The back was flexed maximally, subjects' chin approaching the sternum, and subjects hugged a pillow. Lumbal puncture was done using Quincke needle 25G/27G at L4-5 intervertebral gap until the it reached subarachnoid space (confirmed by free flow cerebrospinal fluid). Data recorded were the number of attempt for the successful spinal puncture, the number of spinal needle-bone contact and blood vessel puncture incidence. Data was analyzed by using Statistical Package for Social Scientist (SPSS), for numerical data using unpaired T-test or Mann-Whitney-U test, for categorical data using Chi-square test or Fischer Exact's Test. Data normality was tested by Kolmogorov-Smirnov test. Significant value is p\<0.05.
1,192,113. Derivatives of dipropylacetic or dipropylhaloacetic acids. LABORATOIRES J. BERTHIER S.A. 9 May, 1968 [24 May, 1967], No. 22110/68. Heading C2C. The invention comprises esters of dipropylacetic acid with 3- or 4-acetylphenol or with 1- or 2-naphthol esters of dipropylhaloacetic acid with 1- or 2-naphthal, or amides of dipropylacetic acid with 3 - or 4 - acetylaniline or with 1- or 2-naphthylamine and amides of dipropylhaloacetic acid with 1- or 2-naphthylamine. The compounds are prepared by reacting the appropriate acid chloride with the corresponding hydroxy compound or with the appropriate amine. Pharmaceutical compositions, suitable for oral or parenteral administration and having tranquillizing activity, contain the above novel compounds in association with pharmaceutically acceptable diluents or carriers.
All patients received premedication prior to paclitaxel (see WARNINGSand PRECAUTIONS, Hypersensitivity Reactionssections). The frequency and severity of HSRs were not affected by the dose or schedule of paclitaxel administration. In the Phase 3 second-line ovarian study, the 3-hour infusion was not associated with a greater increase in HSRs when compared to the 24-hour infusion. Hypersensitivity reactions were observed in 20% of all courses and in 41% of all patients. These reactions were severe in less than 2% of the patients and 1% of the courses. No severe reactions were observed after course 3 and severe symptoms occurred generally within the first hour of paclitaxel infusion. The most frequent symptoms observed during these severe reactions were dyspnea, flushing, chest pain, and tachycardia. Abdominal pain, pain in the extremities, diaphoresis, and hypertension were also noted. 

The minor hypersensitivity reactions consisted mostly of flushing (28%), rash (12%), hypotension (4%), dyspnea (2%), tachycardia (2%), and hypertension (1%). The frequency of hypersensitivity reactions remained relatively stable during the entire treatment period.

Chills, shock, and back pain in association with hypersensitivity reactions have been reported.
The ability to incorporate iodoform, tetracycline and a combination of iodoform/tetracycline into root canal gutta percha points is described. The iodoform, tetracycline and iodoform/tetracycline combination are bound within the gutta percha points. They act as a reservoir of antimicrobial that is capable of diffusing onto the surface of the gutta percha thereby inhibiting the colonization of bacteria on the gutta percha points and within the root canal system. Tetracycline is capable of coalescing within the dentinal tubules to inhibit long term microbial growth. These medicated gutta percha points are site specific, surface acting antimicrobial gutta percha points. A method of the usage and delivery of amorphous form iodoform gutta percha, iodoform/tetracycline gutta percha, or tetracycline gutta percha within a heated compule with a pressure plunger by delivering the thermo-softened heat labile amorphous form via a pressure extrusion system through a cannula into the prepared root canal system.
Patients will be imaged with imaging device (Presygen™/si-1) during surgical procedure. Image surgical area. Surgical procedure will follow standard of care. No clinical decisions will be made on device readings. A surgeon will complete a survey regarding his assessment of the imaging device.
BW is an important economic trait in sheep that influences growth and development. Currently, most studies have used a single approach to screen genes associated with BW traits in sheep. To address this limitation, we conducted a genome-wide association study (GWAS) covering four different BW periods: birth, weaning, 6 months, and 12 months. Five new candidate genes: MAP3K1, ANKRD55, ABCB1, MEF2C and TRNAW-CCA-87 were screened using a combination of GWAS and quantitative trait loci analysis in sheep. Additionally, five genes were subjected to Gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses. These genes were primarily enriched in pathways related to growth hormone and energy metabolism. The results demonstrated that the above genes potentially influenced the growth and development of sheep. The five new candidate genes are closely related to the BW trait in sheep, which will be valuable for understanding the genetic mechanisms underlying BW traits and for guiding sheep breeding.
After being transferred onto a tilt table, subject with complete SCI will lie in a rested, supine position in which the study drug, pyridostigmine bromide (60 mg) will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.
Obesity represents a growing public health concern and is closely associated with metabolic complications such as diabetes and fatty liver disease. Anti-obesity medications currently available have limited efficacy in weight loss and are often accompanied by adverse effects. This study proposes a localized photothermal therapy (PTT) combined with adipocyte-targeted delivery of rosiglitazone (RSG) to address obesity. Specifically, cationic albumin nanoparticles (cNPs) were synthesized to deliver RSG precisely to white adipocytes, stimulating the browning process. An IR780-loaded thermosensitive hydrogel was injected and allowed to gel in situ to afford a subcutaneous reservoir that enables localized PTT and controlled release of RSG cNPs. Notably, cNPs significantly enhanced the internalization efficiency in adipocytes in vitro and prolonged the therapeutic retention in the adipose tissue in vivo. Co-administration of RSG cNPs and PTT substantially reduced fat content, induced browning in white adipose tissue in diet-induced obese mice, and mitigated complications such as insulin resistance, fatty liver, and hyperlipidemia. The increased expression of uncoupling protein 1 contributes to enhancing energy expenditure and facilitating adipose metabolism, thereby effectively combating obesity. This therapeutic approach integrates localized PTT with adipocyte-targeted delivery to combat the global obesity epidemic thus offering a promising solution with reduced systemic toxicity and enhanced efficacy. STATEMENT OF SIGNIFICANCE: Cationic albumin nanoparticles are capable of efficient internalization in adipocytes, which may enhance drug targeting to adipose tissue. The combination of rosiglitazone-loaded cationic albumin nanoparticles and local hyperthermia effectively reduces lipid accumulation in adipocytes and induces an upregulated expression of uncoupling protein 1. The combination therapy effectively inhibits fat accumulation, induces adipocyte browning, and regulates systemic metabolism in diet-induced obese mice.
Low-Level Light Therapy; LLLT is also called PhotoBioModulation; PBM, which is a new type of interventional therapy.LLLT applies low-level lasers or light-emitting diodes(LEDs) to the human body for treatment. The wavelength of irradiated light is between red light(630-700 nm) and near-infrared light(700nm-1,100nm), and leads to a positive biological effect. It is a safe, painless, non-invasive treatment method. When LLLT is applied to the brain, it can pass through the scalp, head bone and reach the brain, and then stimulating the photochemical reaction in the cells, This is called transcranial Low-Level Laser Therapy (t-LLLT) or transcranial Photobiomodulation(t-PBM). tLLLT has existed since 1967, and more than thousands of scientific studies have shown that photons can stimulate biological responses and promote the normal work of cells. t-LLLT can treat a variety of diseases, such as emotional symptoms, lower back pain, weight loss, skin anti-aging, wound healing, etc. There are no reports of side effects. The main mechanism is similar to the photosynthesis of plants. It absorbs light and produces chemical reactions, supports mitochondrial function, and significantly increases the production of ATP(the main carrier of energy in cells.)in the brain, so as to function work better and achieve self-repair. This research uses Dr. Tai's energy cap, the manufacturer is Topunion Globaltek Inc., which passed the certification of the Ministry of Health and Welfare(MOHW) for medical device in 2019. It has been modified to the second generation and is now on the market. It basically provides two kinds of red light (wavelength of 660nm) and near-infrared light(wavelength of 850nm), which is mainly used at home. The research intervention will be conducted for four weeks, pre-tests and post-tests will be conducted as indicators to evaluating sleep and psychological symptoms.
Severe, potentially life-threatening, and fatal skin reactions have been reported. These include cases of Stevens-Johnson syndrome and toxic epidermal necrolysis. Hypersensitivity reactions have also been reported and were characterized by rash, constitutional findings, and sometimes, organ dysfunction, including hepatic failure. Discontinue ISENTRESS and other suspect agents immediately if signs or symptoms of severe skin reactions or hypersensitivity reactions develop (including, but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, hepatitis, eosinophilia, angioedema). Clinical status including liver aminotransferases should be monitored and appropriate therapy initiated. Delay in stopping ISENTRESS treatment or other suspect agents after the onset of severe rash may result in a life-threatening reaction.
A sterile product containing a substance embedded in a carrier is produced by use of a supercritical gas. In one embodiment, a mixture is formed of a substance, carrier and supercritical gas such as nitrous oxide or carbon dioxide, and the supercritical gas is separated from the substance and carrier to obtain the product. In another embodiment, the supercritical gas contains the substance, and is mixed with an atomized organic solvent containing the carrier to form a mixture. The supercritical gas extracts the solvent, and is separated from the substance and carrier to produce the product. Alternatively, the carrier can be in the supercritical gas and the substance in the solvent, or both the substance and carrier can be in the solvent. Atomization and formation of the mixture can be carried out by feeding the supercritical gas and solvent through a nozzle into a spray tower or column. The supercritical gas containing the solvent is separated to obtain the product in the form of a dry powder containing spheres of the carrier having the substance embedded therein. The carrier can be polymers, lipids, lecithins or waxes, and the substance can be medicines, toxins, viruses, diagnostic materials, herbicides, insecticides or pesticides. An apparatus for carrying out the method contains a spray tower and other means for performing the method steps.
PROBLEM TO BE SOLVED: To obtain an oral solid preparation having excellent foul breath- preventing activity by compounding a high density forming component and a foul breath-preventing component at a specific ratio. SOLUTION: This preparation is composed of (a) 15-90wt.% foaming component and (b) 0.01-10wt.% foul breath-preventing component. The compounding ratio (a:b) of the components is (10:1) to (1000:1), preferably (100:1) to (500:1). The (a) component is preferably a carbonic acid gas component containing an organic acid and a carbonate salt, and a preferable example includes sodium hydrogen carbonate. The (b) component is preferably sodium copper chlorophylline. Further, it is preferable to compound menthol for imparting fresh feeling. The composition is formulated into a tablet such as a troche or a solid preparation such as a candy or a starch-based candy which is dissolved in a mouth to administer.  The inside of the mouth is washed by foaming in the mouth, especially fur existing on the backside of the tong is removed, papillae filiformie on the backside of the tong are uncovered and the foul breath-preventing component acts on the papillae filiformie to synergistically enhance the foul breath-preventing effect.
A combination of pegylated-interferon (PEG-IFN) with ribavirin has been the choice for treating chronic hepatitis C (CHC) patients. In addition to the high cost, the treatment takes 6 to 12 months and often brings significant adverse reactions to some patients. It would therefore be beneficial to include a pre-treatment evaluation and post-treatment monitoring system to maximize the efficacy of CHC therapy. We have established a molecular diagnosis tool for assessing the efficacy of interferon combined therapy for CHC patients prior to treatment. This diagnostic tool is characterized with a prediction model consisting single nucleotide polymorphisms (SNPs) strongly associated with interferon efficacy in treating CHC patients. The prediction model has been validated by hepatitis C samples in Taiwan, and it achieved 80 % accuracy, higher than the current efficacy rates. Supplemented with the viral genotype information would further increase the prediction accuracy to 85%.

In this project, we aim to analyze patients' gene expression profiling during the treatment. The current study will focus on 30 PEG-IFN and ribavirin treated patients with HCV genotype 1 infection. After the responding status of those patients has been confirmed, we will compare gene expression profiling among the different responses before and during treatment. By using this information, we can properly select the candidate genes, and establish a monitoring model with these biomarkers. This monitoring model can thus be applied to assess the efficacy of PEG-IFN plus ribavirin combination treatment.
The invention belongs to the field of functional materials and particularly relates to mild deep cleansing oil having a skin-care effect and a preparation method thereof. The mild deep cleansing oil contains 79 to 89.9 volume percent of vegetable oil, 10 to 20 volume percent of emulsifier, 0.1 to 1 percent of essence and 0 to 5 volume percent of wetting agent; and the total volume of the components is 100 percent. The deep cleansing oil prepared according to the formula is mild and has a skin-care effect. The method comprises: mixing the vegetable oil and emulsifier, and stirring uniformly at normal temperature; and adding corresponding essence according to different skin-care needs. For preparing deep cleansing oil for dye skin, a proper amount of wetting agent is added, and finally the mixture is continuously and uniformly stirred at normal temperature. When the method is used, different kinds of deep cleansing oil for different skin qualities are prepared respectively according to different formulae. The deep cleansing oil can completely cleanse thick waterproof mascara, foundation make-up and lipstick on faces. The deep cleansing oil can be prepared easily at low cost and is insusceptible to pollution by microorganisms, and an anticorrosion problem is well solved.
All patients received gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 of a 28 day cycle. Pomalidomide was administered orally on days 1-21 at doses escalated from 2 mg to 10 mg daily.
Participants will start with an 8-week run in period with vismodegib 150 mg dose by mouth daily. Participants will take vismodegib for the first 8 weeks, then start personalized dosing based on specific model.
The invention discloses a traditional Chinese medicine composition for treating osteomyelitis and a preparation method thereof. The traditional Chinese medicine composition is prepared from leucosceptrumcanum Smith, boehmeriamacrophylla, aeginetiasinensis G. Beck, nepalsaurauia bark, root of gomphandratetrandra, aristolochiakwangsiensis Chun et How ex, elaeagnusloureirii Champ., sagittariatrifolia, ligulariadentate, root of disporumbodinieri (Levl. et Vant.) Wang et Tang, aralia undulata Hand.-Mazz, aspleniumprolongatum Hook., renantheracoccinea, elsholtziamyosurusdunn, root of aralia dumetorum Hand.-Mazz., root of fragrant heteropanax, aeginetiaindica, saviamiltiorrhiza and root of trichiliasinensisBentv. According to different characters of all the medicine, boehmeriamacrophylla, aeginetiasinensis G. Beck, sagittariatrifolia, aralia undulata Hand.-Mazz, renantheracoccinea, root of aralia dumetorum Hand.-Mazz., root of fragrant heteropanax, aeginetiaindica and saviamiltiorrhiza are extracted by using an enzymolysis approach, leucosceptrumcanum Smith, nepalsaurauia bark, root of gomphandratetrandra, aristolochiakwangsiensis Chun et How ex, elaeagnusloureirii Champ., ligulariadentate, root of disporumbodinieri (Levl. et Vant.) Wang et Tang, aspleniumprolongatum Hook.andelsholtziamyosurusdunn are extracted by using a recovered ethanol solution, root of trichiliasinensisBentv is ground into powder and blended with sesame oil, obtained extracts are mixed and then are added with auxiliary materials, so that externally used past is prepared according to a conventional process. The traditional Chinese medicine composition is reasonable in recipe, quick and significant in effect and free of side effect, and the efficacy is lasting and deep into a focus.
Patients will begin taking the capsules at the onset of headache symptoms. Onset is defined as the point in time the participant feels that it is necessary to take the test product for relief of symptoms. When the participant decides to take the test product, they will report symptoms in the headache diary prior to taking the product and rate their symptoms on a 10-point Mankoski scale. After consuming the product, the participant will complete a Mankoski scale at 15 minutes, 30 minutes and 1 hour after taking the product. If needed the participant will be allowed to take alternative medication (alternative treatment) after an hour after taking the product. If alternative medication is taken, the participant will record this in their headache diary.
BACKGROUND: Assessment of kidney function is necessary for prescribing renally excreted drugs. The estimated glomerular filtration rate (eGFR) routinely reported by laboratories is indexed to a body surface area (BSA) of 1.73 m2. In obese patients, the indexed eGFR may underestimate directly measured GFR.
AIMS: To determine the prevalence of obesity in patients with chronic kidney disease (CKD) and examine the effect of adjusting the indexed eGFR for patient BSA (deindexing) across CKD Stages 2-5.
METHODS: We conducted a cross-sectional study of 575 adults with stable CKD from two general nephrology clinics over 6 months. Dialysis and kidney transplant patients were excluded. We used four equations (Mosteller, Dubois, Haycock and Schlich) to determine BSA based on actual body weight and applied Bland-Altman plots and piecewise linear regression to examine the relationship between deindexed and indexed eGFR.
RESULTS: The median age was 68 years (58% male). The prevalence of overweight and obesity was 31% and 47% respectively. Mean body mass index was 29.7 kg/m2. The Schlich equation for BSA produced the smallest adjustment in eGFR, while the Haycock equation produced the largest adjustment. Males experienced the largest change in eGFR from deindexing because of larger BSAs. Although bias became increasingly positive with higher eGFR, the linear regression stratified by CKD stage indicated that deindexing had little impact with eGFR <45 mL/min/1.73 m2.
CONCLUSIONS: In CKD, deindexing the Chronic Kidney Disease Epidemiology Collaboration eGFR may not be necessary when the eGFR is <45 mL/min/1.73 m2, particularly if the patient is female.